The molecular basis of von Willebrand disease

International Journal of Clinical and Laboratory Research

Volumn 29, Issue 1, 1999, Pages 1-7

  Mohlke, K L ^a   Nichols, W C ^c   Ginsburg, D ^a,b  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Molecular defects; von Willebrand disease

Indexed keywords

VON WILLEBRAND FACTOR;

FRAMESHIFT MUTATION; GENETICS; HUMAN; MISSENSE MUTATION; REVIEW; VON WILLEBRAND DISEASE;

FRAMESHIFT MUTATION; HUMANS; MUTATION, MISSENSE; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 0032978845     PISSN: 09405437     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005990050054     Document Type: Review

References (55)

1. Ruggeri ZM. von Willebrand factor. J Clin Invest 1997; 99: 559.
2. Wagner DD. The Weibel-Palade body: the storage granule for von Willebrand factor and P-selectin. Thromb Haemost 1993; 70: 105.
3. Sadler JE. von Willebrand factor. J Biol Chem 1991; 266: 22777.
4. Nichols WC, Ginsburg D, von Willebrand disease. Medicine 1997; 76: 1.
5. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69: 454.
6. Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993; 123: 893.
7. Berliner SA, Seligsohn U, Zivelin A, Zwang E, Sofferman G. A relatively high frequency of severe (type III) von Willebrand's disease in Israel. Br J Haematol 1986; 62: 535.
8. Weiss HJ, Ball AP, Mannucci PM. Incidence of severe von Willebrand's disease. N Engl J Med 1982; 307: 127.
9. Mannucci PM, Bloom AL, Larrieu MJ, Nilsson IM, West RR. Atherosclerosis and von Willebrand factor. I. Prevalence of severe von Willebrand's disease in western Europe and Israel. Br J Haematol 1984; 57: 163.
10. Zhang ZP, Blombäck M, Egberg N, Falk G, Anvret M. Characterization of the von Willebrand factor gene (VWF) in von Willebrand disease type III patients from 24 families of Swedish and Finnish origin. Genomics 1994; 21: 188.
11. Zhang ZP, Lindstedt M, Blombäck M, Anvret M. Effects of the mutant von Willebrand factor gene in von Willebrand disease. Hum Genet 1995; 96: 388.
12. Hoyer LW, Rizza CR, Tuddenham EGD, Carta CA, Armitage H, Rotblat F. Von Wiliebrand factor multimer patterns in von Willebrand's disease Br J Haematol 1983; 55: 493.
13. Weiss HJ, Piétu G, Rabinowitz R, Girma J-P, Rogers J, Meyer D. Heterogeneous abnormalities in the multimeric structure, antigenic properties, and plasma-platelet content of factor VIII/von Willebrand factor in subtypes of classic (type I) and variant (type IIA) von Willebrand's disease. J Lab Clin Med 1983; 101:411.
14. Mannucci PM, Lombardi R, Bader R, Vianello L, Federici AB, Solinas S, Mazzucconi MG, Mariani G. Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor. Blood 1985; 66: 796.
15. Mohlke KL, Ginsburg D. von Willebrand disease and quantitative deficiency of von Willebrand factor. J Lab Clin Med 1997; 130: 252.
16. Eikenboom JCJ, Matsushita T, Reitsma PH, Tuley EA, Castaman G, Briët E, Sadler JE. Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor. Blood 1996; 88: 2433.
17. Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood 1981; 57: 1140.
18. Meyer D, Fressinaud E, Gaucher C, Lavergne J-M, Hilbert L, Ribba A-S, Jorieux S, Mazurier C, and INSERM Network on Molecular Abnormalities in von Willebrand Disease. Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene. Thromb Haemost 1997; 78: 451.
19. Lyons SE, Bruck ME, Bowie EJW, Ginsburg D. Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem 1992; 267: 4424.
20. Dent JA, Galbusera M, Ruggeri ZM. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest 1991; 88: 774.
21. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci USA 1990; 87: 6306.
22. Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223.
23. Tsai H-M, Sussman II, Ginsburg D, Lankhof H, Sixma JJ, Nagel RL. Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1. Blood 1997; 89: 1954.
24. Gaucher C, Diéval J, Mazurier C. Characterization of von Willebrand factor gene defects in two unrelated patients with type IIC von Willebrand disease. Blood 1994; 84: 1024.
25. Schneppenheim R, Thomas KB, Krey S, Budde U, Jessat U, Sutor AH, Zieger B. Identification of a candidate missense mutation in a family with von Willebrand disease type IIC. Hum Genet 1995; 95: 681.
26. Gaucher C, Mazurier C. Phenotype IIC von Willebrand disease: the expression of three mutant recombinant von Willebrand factors (VWF) confirms the importance of the D2 domain of VWF propeptide in the multimer assembly process (abstract). Br J Haematol 1996; 93 [Suppl 2]: 15.
27. Schneppenheim R, Brassard J, Krey S, Budde U, Kunicki TJ, Holmberg L, Ware J, Ruggeri ZM. Defective dimerization of von Willebrand factor subunits due to a Cys → Arg mutation in type IID von Willebrand disease. Proc Natl Acad Sci USA 1996; 93: 3581.
28. Ruggeri ZM, Pareti FI, Mannucci PM, Ciavarella N, Zimmerman TS. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med 1980: 302: 1047.
29. Holmberg L, Dent JA, Schneppenheim R, Budde U, Ware J, Ruggeri ZM, von Willebrand factor mutation enhancing interaction with platelets in patients with normal multimeric structure. J Clin Invest 1993; 91: 2169.
30. Rabinowitz I, Tuley EA, Mancuso DJ, Randi AM, Firkin BG, Howard MA, Sadler JE. von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib. Proc Natl Acad Sci USA 1992; 89: 9846.
31. Hilbert L, Gaucher C, Mazurier C. Identification of two mutations (Arg611Cys and Arg611His) in the A1 loop of von Willebrand factor (vWF) responsible for type 2 von Willebrand disease with decreased platelet-dependent function of vWF. Blood 1995; 86: 1010.
32. Mannucci PM, Lombardi R, Castaman G, Dent JA, Lattuada A, Rodeghiero F, Zimmerman TS. von Willebrand disease "vicenza" with larger-than-normal (supranormal) von Willebrand factor multimers. Blood 1988; 71: 65.
33. Zieger B, Budde U, Jessat U, Zimmermann R, Simon M, Kätze R, Sutor AH. New families with von Willebrand disease type 2M (Vicenza). Thromb Res 1997; 87: 57.
34. Ciavarella G, Ciavarella N, Antoncecchi S, De Mattia D, Ranieri P, Dent J, Zimmerman TS, Ruggeri ZM. High-resolution analysis of von Willebrand factor multimeric composition defines a new variant of type I von Willebrand disease with aberrant structure but presence of all size multimers (type IC). Blood 1985; 66: 1423.
35. Lopez-Fernandez MF, Gonzalez-Boullosa R, Blanco-Lopez MJ, Perez M, Batlle J. Abnormal proteolytic degradation of von Willebrand factor after desmopressin infusion in a new subtype of von Willebrand disease (ID). Am J Hematol 1991; 36: 163.
36. Montgomery RR, Dent J, Schmidt W, Kyrle P, Niessner H, Ruggeri ZM, Zimmerman TS. Hereditary persistence of circulating pro von Willebrand factor (pro-vWf) (abstract). Circulation 1986; 74 [Suppl II]: II-406.
37. Mazurier C, von Willebrand disease masquerading as haemophilia A. Thromb Haemost 1992; 67: 391.
38. Eikenboom JCJ, Reitsma PH, Peerlinck KMJ, Briët E. Recessive inheritance of von Willebrand's disease type I. Lancet 1993; 341: 982.
39. Miller CH, Graham JB, Goldin LR, Elston RC. Genetics of classic von Willebrand's disease. I. Phenotypic variation within families. Blood 1979; 54: 117.
40. Abildgaard CF, Suzuki Z, Harnson J, Jefcoat K, Zimmerman TS. Serial studies in von Willebrand's disease: variability versus "variants". Blood 1980; 56: 712.
41. Orstavik KH, Magnus P, Reisner H, Berg K, Graham JB, Nance W. Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet 1985; 37: 89.
42. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69: 1691.
43. Triplett DA. Laboratory diagnosis of von Willebrand's disease. Mayo Clin Proc 1991; 66: 832.
44. Rickles FR, Hoyer LW, Rick ME, Ahr DJ. The effects of epinephrine infusion in patients with von Willebrand's disease. J Clin Invest 1986; 57: 1618.
45. Takeuchi M, Nagura H, Kaneda T. DDAVP and epinephrine-induced changes in the localization of von Willebrand factor antigen in endothelial cells of human oral mucosa. Blood 1988; 72: 850.
46. Ginsburg D, Sadler JE, von Willebrand disease: a database of point mutations, insertions, and deletions. Thromb Haemost 1993; 69: 177.
47. Nichols WC, Liepnieks JJ, McKusick VA, Benson MD. Direct sequencing of the gene for Maryland/German familial amyloidotic polyneuropathy type II and genotyping by allele-specific enzymatic amplification. Genomics 1989; 5: 535.
48. Szabo CI, King M-C. Population genetics of BRCA1 and BRCA2. Am J Hum Genet 1997; 60: 1013.
49. Liu B, Parsons R, Papadopoulos N, Nicolaides NC, Lynch HT, Watson P, Jass JR, Dunlop M, Wyllie A, Peltomäki P, Chapelle A de la, Hamilton SR, Vogelstein B, Kinzler KW. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med 1996; 2: 169.
50. Shovlin CL. Molecular defects in rare bleeding disorders: hereditary haemorrhagic telangiectasia. Thromb Haemost 1997; 78: 145.
51. Nichols WC, Cooney KA, Mohlke KL, Ballew JD, Yang A, Bruck ME, Reddington M, Novak EK, Swank RT, Ginsburg D, von Willebrand disease in the RIIIS/J mouse is caused by a defect outside of the von Willebrand factor gene. Blood 1994; 83: 3225.
52. Mohlke KL, Nichols WC, Westrick RJ, Novak EK, Cooney KA, Swank RT, Ginsburg D. A novel modifier gene for plasma von Willebrand factor level maps to distal mouse chromosome 11. Proc Natl Acad Sci USA 1996; 93: 15352.
53. Mohlke KL, Purkayastha AA, Westrick RJ, Smith PL, Petryniak B, Lowe JB, Ginsburg D, Mvwf. a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase. Cell 1999; 96: 111.
54. Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71: 520.
55. Cattaneo M, Simoni L, Gringeri A, Mannucci PM. Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor. Br J Haematol 1994; 86: 333.